Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization
NCT ID: NCT02184897
Last Updated: 2016-07-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
24 participants
INTERVENTIONAL
2014-07-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
NCT01246076
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
NCT01772420
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
NCT00910858
A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
NCT05007652
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
NCT00502112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AM group
Lenograstim is administered at 8 am and apheresis is started at 10 am on D4.
lenograstim 10 microgram/kg/day
PM group
Lenograstim is administered at 6 pm and apheresis is started at 8 am on D5
lenograstim 10 microgram/kg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lenograstim 10 microgram/kg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* informed consent
* ECOG 0-1
* autologous stem cell transplant candidate among patients with multiple myeloma
Exclusion Criteria
* history of failure to mobilize hematopoietic stem cells
* history of G-CSF administration within 2 weeks before enrollment to this study
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cheolwon Suh
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center, University of Ulsan College of Medicine
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMC_MM01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.